|
Name |
(3S)-3-[[(3R)-7,7-dimethyl-3-(2-methylbut-3-en-2-yl)-2-oxo-1H-pyrano[2,3-g]indol-3-yl]methyl]-8a-hydroxy-3,6,7,8-tetrahydro-2H-pyrrolo[1,2-a]pyrazine-1,4-dione
|
| Molecular Formula | C26H31N3O5 | |
| IUPAC Name* |
(3S)-3-[[(3R)-7,7-dimethyl-3-(2-methylbut-3-en-2-yl)-2-oxo-1H-pyrano[2,3-g]indol-3-yl]methyl]-8a-hydroxy-3,6,7,8-tetrahydro-2H-pyrrolo[1,2-a]pyrazine-1,4-dione
|
|
| SMILES |
CC1(C=CC2=C(O1)C=CC3=C2NC(=O)[C@]3(C[C@H]4C(=O)N5CCCC5(C(=O)N4)O)C(C)(C)C=C)C
|
|
| InChI |
InChI=1S/C26H31N3O5/c1-6-23(2,3)25(14-17-20(30)29-13-7-11-26(29,33)22(32)27-17)16-8-9-18-15(19(16)28-21(25)31)10-12-24(4,5)34-18/h6,8-10,12,17,33H,1,7,11,13-14H2,2-5H3,(H,27,32)(H,28,31)/t17-,25+,26?/m0/s1
|
|
| InChIKey |
GRGBTCMGCXJTOO-OQKZOFOUSA-N
|
|
| Synonyms |
Notoamide M
|
|
| CAS | NA | |
| PubChem CID | 101463299 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 465.5 | ALogp: | 2.3 |
| HBD: | 3 | HBA: | 5 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 108.0 | Aromatic Rings: | 5 |
| Heavy Atoms: | 34 | QED Weighted: | 0.592 |
| Caco-2 Permeability: | -4.906 | MDCK Permeability: | 0.00002460 |
| Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.2 | 20% Bioavailability (F20%): | 0.079 |
| 30% Bioavailability (F30%): | 0.039 |
| Blood-Brain-Barrier Penetration (BBB): | 0.518 | Plasma Protein Binding (PPB): | 90.99% |
| Volume Distribution (VD): | 0.875 | Fu: | 7.98% |
| CYP1A2-inhibitor: | 0.015 | CYP1A2-substrate: | 0.305 |
| CYP2C19-inhibitor: | 0.178 | CYP2C19-substrate: | 0.856 |
| CYP2C9-inhibitor: | 0.645 | CYP2C9-substrate: | 0.658 |
| CYP2D6-inhibitor: | 0.447 | CYP2D6-substrate: | 0.141 |
| CYP3A4-inhibitor: | 0.943 | CYP3A4-substrate: | 0.934 |
| Clearance (CL): | 2.189 | Half-life (T1/2): | 0.29 |
| hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.134 |
| Drug-inuced Liver Injury (DILI): | 0.437 | AMES Toxicity: | 0.031 |
| Rat Oral Acute Toxicity: | 0.907 | Maximum Recommended Daily Dose: | 0.897 |
| Skin Sensitization: | 0.042 | Carcinogencity: | 0.958 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
| Respiratory Toxicity: | 0.306 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002535 | ![]() |
0.736 | D06XZW | ![]() |
0.226 | ||
| ENC004604 | ![]() |
0.551 | D02IQY | ![]() |
0.225 | ||
| ENC002052 | ![]() |
0.520 | D06YFA | ![]() |
0.211 | ||
| ENC002366 | ![]() |
0.516 | D05AFR | ![]() |
0.210 | ||
| ENC002534 | ![]() |
0.516 | D0Y7RW | ![]() |
0.207 | ||
| ENC002536 | ![]() |
0.516 | D0IL7L | ![]() |
0.206 | ||
| ENC002365 | ![]() |
0.508 | D08UMH | ![]() |
0.203 | ||
| ENC004071 | ![]() |
0.496 | D0I5DS | ![]() |
0.203 | ||
| ENC004946 | ![]() |
0.477 | D06HBQ | ![]() |
0.202 | ||
| ENC004947 | ![]() |
0.473 | D0X3FX | ![]() |
0.201 | ||